Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
Original Article
M.D. Galsky, B.P. Valderrama, M. Maruzzo, A. Font, T. Ciuleanu, J. Chatzkel, T. Koie, C.J. Hoimes, J. Puente, Y. Zakharia, E. Rosenbaum, K. Boehm, Y. Loriot, J. Bedke, T.B. Powles, A. Necchi, P. Wiechno, C. Álvarez-Fernández, T.-H. Kim, N. Oliveira, T.W. Flaig, H.S. Wirtz, M. Mihm, Q. Huang, A. Rogiers, B.H. Moreno, and A.G.d. Liaño
N Engl J Med 2026;395:338-348
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Please sign in or create an account to take the course.

Facebook
X
LinkedIn
Forward